Áttétes emlőrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• HER2 193
• CDK4/6 49
• PIK3CA 24
• ESR1 11
• PD-L1 10
• BRCA1 2
• PI3K 13
• PARP 7
• BRCA2 2
• AKT 4
• PD-1 10
• STAT3 0
• PTEN 2
• TP53 0
• mTOR 5
• TROP2 4
• STING 0
• VEGF 4
• YAP 0
• PALB2 3
• MMP-9 0
• AR 0
• CXCR4 1
• EGFR 3
• HER3 4
• AMPK 0
• HDAC 1
• JAK 1
• CTNNB1 0
• FGFR 1
• PSMA 0
• ATM 0
• CD40 1
• EZH2 0
• FAK 0
• HIF-1 0
• MUC1 3
• PPAR 0
• BCL-2 1
• CD47 1
• COX-2 0
• ERK 0
• HSP90 0
• IGF1R 0
• IL-6 0
• MDM2 2
• MET 0
• MYC 0
• TNF 0
• B7-H3 1
• CCR5 0
• CSF1R 0
• CTLA-4 1
• JNK 0
• LAG-3 0
• MAPK 0
• NF1 0
• NRF2 0
• RANKL 0
• TIGIT 0

35+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• U.S. Department of Veterans Affairs · IK1

  Evaluating hypertension care delivery in Veterans with rheumatoid arthritis to improve cardiovascular disease prevention

  Durham Va Medical Center· Durham, Egyesült Államok· until 2028. okt.

• NIH NIDA · UG3

  Development of a Novel Treatment for Benzodiazepine Addiction

  University of Mississippi Med Ctr· Jackson, Egyesült Államok· 1 753 289 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NINR · F31

  Clarifying symptom experiences and management strategies for breast cancer survivors with cardiotoxicity: A mixed-methods analysis

  University of South Florida· Tampa, Egyesült Államok· 40 326 USD awarded in fiscal year 2026· until 2028. júl.

• NIH NIAID · R56

  Functional dissection of a novel E2 complex critical for the HPV16 life cycle

  Virginia Commonwealth University· Richmond, Egyesült Államok· 768 308 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · R15

  Mechanotransduction from the tumor microenvironment to the nuclear envelope protein emerin enables nuclear softening during cancer metastasis

  Rowan University· Glassboro, Egyesült Államok· 564 078 USD awarded in fiscal year 2026· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DuoLipo-TNP: Dual-Responsive Liposome Platform for Selective Delivery of Triphosphate Nucleotide Prodrugs in Triple-Negative Breast Cancer

  Cardiff University· Cardiff, Egyesült Királyság· EU contribution 260 348 EUR· until 2029. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Görögország· EU contribution 796 590 EUR· until 2030. dec.· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Mapping antigenic niches of tumor-infiltrating B cells in triple-negative breast cancer (MAP-BC)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 252 180 EUR· until 2028. dec.

• European Commission (Horizon Europe) · HORIZON-ERC

  Re-wiring tumor immune-evasive plasticity with mRNA therapy (PLASTWIRE)

  Fundacio Institut Hospital del Mar D Investigacions Mediques· Barcelona, Spanyolország· EU contribution 2 533 207 EUR· until 2031. nov.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Multispecific theranostic nano-engager platform (Nano-BITE)

  Institut Gustave Roussy· Villejuif, Franciaország· EU contribution 150 000 EUR· until 2028. máj.

  The disease is named only in the funder's project summary, not in the title.

10 of 2354 running projects, newest first. Listed amounts together: 1,3 Mrd USD + 289,4 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

  NCT04740918· Hoffmann-La Roche· Frissítve: 2025. aug. 8.

  “Due to low enrollment, the Sponsor decided to prematurely terminate the study”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

  NCT03742102· AstraZeneca· Forrás

• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  NCT06312176· Merck Sharp & Dohme LLC· Forrás

• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

  NCT04895358· Merck Sharp & Dohme LLC· Forrás

• A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

  NCT05374512· AstraZeneca· Forrás

• A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

  NCT04740918· Hoffmann-La Roche· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 21
• Organoids 7
• CRISPR-Cas Systems 4
• Gene Expression Profiling 63
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 3
• Exome Sequencing 5
• Proteomics 16
• Metabolomics 3
• Mass Spectrometry 1
• Flow Cytometry 9
• Immunohistochemistry 70
• Liquid Biopsy 19
• Circulating Tumor DNA 46
• Xenograft Model Antitumor Assays 109
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 64
• Machine Learning 30
• Deep Learning 23
• Cohort Studies 57
• Genome-Wide Association Study 1

• High-Purity Magnetic Fluidic Isolation of Viable Circulating Tumor Cells Enables Single-Cell Multi-Omics Profiling.

  Anal Chem, 2026. nov.

• Single-Cell Characterization of SPP1-Expressing Macrophages and Their Predicted Interactions With T Cells in the Breast Cancer Bone Metastatic Microenvironment.

  Cancer Rep (Hoboken), 2026. nov.

• CD39-associated myeloid-T-cell coordination within an immunoregulatory neighborhood linked to treatment resistance in triple-negative breast cancer.

  Breast Cancer Res, 2026. aug.

• Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor-Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy.

  Clin Cancer Res, 2026. aug.

  Sarah Sammons

• Exploring platelet-covered and naked circulating tumor cells - a single-cell transcriptomic perspective.

  J Transl Med, 2026. júl.

• Single-cell profiling reveals peripheral blood immune landscape remodelling in breast cancer lymph node metastasis.

  Clin Transl Med, 2026. jún.

• Deciphering the immunological landscape of HR + metastatic breast cancer: insights from single-cell transcriptomics.

  Hum Cell, 2026. máj.

• ModelistsGCN: a multimodal graph convolutional network framework for single-cell spatial transcriptomic cell typing.

  Brief Bioinform, 2026. máj.

• Multi-omics single-cell dissection of malignant epithelial heterogeneity identifies GJB2 as an EMT-driving biomarker in triple-negative breast cancer.

  BMC Med Genomics, 2026. ápr.

• Single-cell transcriptomics identify mechanical-memory-associated cell states in metastatic HR+ breast cancer.

  Breast Cancer Res, 2026. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.